Labcorp

Q2 FY2026 EarningsQ2 FY26 beat consensus across major metrics: revenue reached $3.73B vs. $3.71B expected, and gross margin came in at 29.8% (nearly in-line with the 30.0% mean). Normalized EPS of $4.78 and GAAP EPS of $3.64 both landed within or above consensus ranges, supported by 4.2% organic growth and operational efficiencies. Biopharma Laboratory Services led growth with a 6.5% YoY revenue increase, while Diagnostics revenue rose 5.5%. Guidance was not explicitly quantified in the text, but the $1B share repurchase authorization expansion signals management's confidence in continued cash flow strength.